4 completed, 2 recruiting, 1 active not recruiting. 6 Phase 1, 1 Phase 2.
By phase and status
Follow BI 3000202: new trials by email Literature Review of BI 3000202 trials Research Report on BI 3000202
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood
BI 3000202, Ciclosporin, Itraconazole - Healthy | Phase 1 | Active not recruiting | 16 | 2026-09-01 | 2026-10-13 |
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
BI 3000202 - Healthy, Hepatic Impairment | Phase 1 | Recruiting | 44 | 2026-05-01 | 2026-05-14 |
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
BI 3000202, Placebo - Systemic Lupus Erythematosus | Phase 2 | Recruiting | 405 | 2026-04-20 | 2026-10-28 |
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
BI 3000202, BI 3000202 [14C]-labelled - Healthy | Phase 1 | Completed | 12 | 2025-12-30 | 2026-03-31 |
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
BI 3000202, Rosuvastatin, Digoxin - Healthy | Phase 1 | Completed | 14 | 2025-11-05 | 2025-12-22 |
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
BI 3000202, Placebo, Midazolam - Healthy | Phase 1 | Completed | 40 | 2024-04-09 | 2024-11-13 |
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
BI 3000202, Placebo matching BI 3000202 - Healthy | Phase 1 | Completed | 68 | 2023-07-25 | 2026-06-08 |
Conditions studied
Lupus Erythematosus, Systemic (1)
Sponsors
Boehringer Ingelheim (7)
Countries
Germany (4) · Netherlands (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1) · Colombia (1) · Croatia (1) · Hungary (1) · India (1) · Japan (1) · Mexico (1)
NIH funding
2023 (2), 2025 (2)